Johnson & Johnson (NYSE:JNJ) Receives $235.91 Average PT from Analysts

Johnson & Johnson (NYSE:JNJ) has earned an average rating of “Moderate Buy” from the twenty-seven research firms that are covering the stock, Marketbeat.com reports. Nine research analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $236.5652.

Several brokerages recently weighed in on JNJ. Morgan Stanley set a $262.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. Loop Capital set a $220.00 price target on shares of Johnson & Johnson in a research note on Tuesday, January 27th. Rothschild & Co Redburn upped their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research report on Thursday, February 19th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Finally, Citigroup boosted their target price on Johnson & Johnson from $250.00 to $274.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $238.18 on Friday. The company has a market cap of $573.68 billion, a P/E ratio of 21.55, a P/E/G ratio of 2.40 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a 50-day moving average of $233.35 and a two-hundred day moving average of $207.56. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last 90 days. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently bought and sold shares of the business. Auto Owners Insurance Co boosted its position in shares of Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $6,924,523,000. Capital World Investors purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $2,005,942,000. Laurel Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after acquiring an additional 7,371,687 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: HSBC raised its price target on JNJ to $280 and upgraded to a “buy,” calling for meaningful upside versus current levels — a fresh, high‑profile endorsement that supports longer‑term bullishness. Article Title
• Positive Sentiment: Independent analyst pieces highlight a $280 target and argue JNJ’s recent outperformance (strong YTD and 1‑yr gains) is backed by pipeline and portfolio strength — reinforcing the narrative of further upside for investors who can wait. Why One Analyst Thinks Johnson & Johnson Reaches $280
• Positive Sentiment: JNJ reported a phase I win for its bladder cancer therapy (Erda‑iDRS) with strong responses and manageable safety — clinical progress that could support future revenue if later‑stage trials succeed. JNJ’s Bladder Cancer Therapy Meets Key Goal
• Positive Sentiment: Regulatory progress for TECVAYLI (teclistamab) — J&J submitted a Type II variation to the EMA seeking approval in relapsed/refractory multiple myeloma — an important potential mid‑term revenue catalyst if approved. TECVAYLI Opportunity
• Neutral Sentiment: Johnson & Johnson launched pulsed field ablation tech in Peru — incremental product expansion in med‑tech markets, supportive but unlikely to meaningfully shift near‑term revenue. PFA Peru Launch
• Neutral Sentiment: Industry news (e.g., Monte Rosa supply agreement) and market commentary reassessing JNJ’s valuation after large multi‑year gains — useful context for positioning but not company‑specific catalysts. Monte Rosa Agreement
• Negative Sentiment: Shares slid today even as the broader market rose — coverage notes the drop reflects short‑term profit‑taking and rotation after a strong run, as well as lighter-than-average volume. That intraday weakness outweighed the new buy rating and clinical headlines. JNJ Stock Slides

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.